Life Sciences: Studies in the area of life sciences reported from New York University, Department of Radiology Studies in the area of life sciences reported from New York University, Department of Radiology (NewsRx.com) -- Research findings, 'TriTone: a radiofrequency field (B1)-insensitive T1 estimator for MRI at high magnetic fields,' are discussed...
Joseph S. Dillon Earns Certified Licensing Professional(TM) Designation LOUIS, MO -- (MARKET WIRE) -- 08/13/08 -- Joseph S.Dillon, Senior Vice President and Head of Corporate Development Services and Valuations for The Mattson Jack Group, Inc.
(MattsonJack), has earned the Certified Licensing Professional...
Eurand Reports Recent Developments and Second Quarter 2008 Financial Results * Received approvable letter for New Drug Application (NDA) for EUR-1008 (Zentase(r) * Achieved successful FDA pre-approval inspection of Milan manufacturing facility and successful FDA pre-approval inspection of raw material supplier...
Eurand Reports Recent Developments and Second Quarter 2008 Financial Results * Received approvable letter for New Drug Application (NDA) for EUR-1008 (Zentase(r)) * Achieved successful FDA pre-approval inspection of Milan manufacturing facility and successful FDA pre-approval inspection of raw material supplier...
Eurand Reports Recent Developments and Second Quarter 2008 Financial Results * $25 million at closing * $5 million, plus interest, at the first anniversary of the closing * $5 million, plus interest, at the second anniversary of the closing PRODUCT DEVELOPMENT PIPELINE UPDATES: EUR-1008 -- Zentase(r) * On June 18,...
Epigenomics AG Reports First Half of 2008 Results GMT+2 /HUGIN /Source: Epigenomics AG /GER: ECX /ISIN: DE000A0BVT96 Key Figures (in EUR thousand) * Revenues: 1,511 in H1 2008; increased by 13% (H1 2007: 1,343) * EBIT: -5,888 in H1 2008; improved by 15% (H1 2007: -6,949) * Net loss: -5,632...
Epigenomics AG Reports First Half of 2008 Results GMT+2 /HUGIN /Source: Epigenomics AG /GER: ECX /ISIN: DE000A0BVT96 Key Figures (in EUR thousand) * Revenues: 1,511 in H1 2008; increased by 13% (H1 2007: 1,343) * EBIT: -5,888 in H1 2008; improved by 15% (H1 2007: -6,949) * Net loss: -5,632...
Nonpharmaceutical Fentanyl-Related Deaths --- Multiple States, April 2005--March 2007 increases in overdoses were reported among illicit drug users in Camden, New Jersey, via the CDC Epidemic Information Exchange (Epi -X).This alert elicited reports of similar increases in overdoses in other parts of New Jersey, and...
Syngene - New Gel Doc System Features Lightly Cooled Camera New Gel Doc System Features Lightly Cooled Camera - To Guarantee Excellent Results with Low Emission Fluorescence Applications July 23rd 2008 Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to...
'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinc LOUIS, MO -- (MARKET WIRE) -- 07/23/08 -- In a survey conducted by The Mattson Jack Group, Inc., oncology key opinion leaders (KOLs) have identified 'triple-negative' patients, or patients whose tumors do not overexpress HER2, the estrogen...
The Changing Face of Vision Marketing Create a personalized experience to deliver what your target market desires.The vision market is changing and evolving.
What are you doing to keep up?
LASIK still holds the top spot as most popular elective procedure, but in today's...
'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinc 'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinci's CancerNSight(TM) (Marketwire Via Acquire Media NewsEdge) ST.LOUIS, MO, July 23 / MARKET WIRE/ -- In a survey conducted by...
'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinc - In a survey conducted by , oncology key opinion leaders (KOLs) have identified 'triple-negative' patients, or patients whose tumors do not overexpress HER2, the estrogen receptor (ER) or progesterone receptor (PR),as the biggest unmet need...
'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinc In a survey conducted by , oncology key opinion leaders (KOLs) have identified 'triple-negative' patients, or patients whose tumors do not overexpress HER2, the estrogen receptor (ER) or progesterone receptor (PR),as the biggest unmet need...
'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinc LOUIS, MO, July 23 / MARKET WIRE/ -- In a survey conducted by The Mattson Jack Group, Inc., oncology key opinion leaders (KOLs) have identified 'triple-negative' patients, or patients whose tumors do not overexpress HER2, the estrogen...
The Mattson Jack Group, Inc.: 'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, A - In a survey conducted by , oncology key opinion leaders (KOLs) have identified 'triple-negative' patients, or patients whose tumors do not overexpress HER2, the estrogen receptor (ER) or progesterone receptor (PR),as the biggest unmet need...
'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinc -- In a survey conducted by , oncology key opinion leaders (KOLs) have identified 'triple-negative' patients, or patients whose tumors do not overexpress HER2, the estrogen receptor (ER) or progesterone receptor (PR),as the biggest unmet...
'Triple-Negative' Patients Are Biggest Unmet Need in Metastatic Breast Cancer, According to MattsonJack DaVinc LOUIS, MO, July 23 / MARKET WIRE/ -- In a survey conducted by The Mattson Jack Group, Inc., oncology key opinion leaders (KOLs) have identified 'triple-negative' patients, or patients whose tumors do not overexpress HER2, the estrogen...
Half of kids with peanut allergy don't have Epi-Pen -0400 (Reuters Health) By Anne Harding NEW YORK (Reuters Health) - Children with peanut allergies may run the risk of not receiving life-saving treatment for a severe allergic reaction called anaphylaxis because they don't have their...
Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development Targeting inherited mitochondrial diseases as an archetype for diseases of aging SAN JOSE, Calif., July 15 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today that ...
Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development Targeting inherited mitochondrial diseases as an archetype for diseases of aging SAN JOSE, Calif., July 15 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA, announced today that ...
Panacea gets WHO prequalification for pentavalent vaccine Panacea Biotec, a leading vaccine manufacturing company, has received WHO prequalification for its fully liquid innovative combination pentavalent vaccine, EasyFive against five deadly infectious diseases (DTwP + Hep B+ Hib) of early...
EpiVax Receives $600,000 Grant to Develop Treatment for Diabetes from National Institutes of Health - EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health...
Eurand's pancrealipase pills get approvable letter from US FDA Eurand NV, a specialty pharmaceutical company has received an approvable letter from the US Food and Drug Administration (FDA) for the company's New Drug Application (NDA) for EUR-1008 (pancrealipase capsules) for the treatment of exocrine...
GSK, Mpex Pharma enter drug development pact GlaxoSmithKline (GSK) and Mpex Pharmaceuticals announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialisation of novel medicines for bacterial diseases.The collaboration provides...
